Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation. The company was founded in 2007 and is headquartered in Beijing, China.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Li, Lin

Employees

629

Website

www.chemclin.com

IPO Date

2021-04-09

Headquarters

Incubator Building, 1st and 6th Floors, Beike Modern Manufacturing Park, No. 7 Fengxian Middle Road, Yongfeng Base, Haidian District, Beijing 100094, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.